Terms: = Breast cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Treatment
81 results:
1. Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced breast cancer Receiving Palbociclib: Results From the TREnd Trial.
Migliaccio I; Romagnoli D; Galardi F; De Luca F; Biagioni C; Curigliano G; Criscitiello C; Minisini AM; Moretti E; Risi E; Guarducci C; Nardone A; Biganzoli L; Benelli M; Malorni L
JCO Precis Oncol; 2024 Feb; 8():e2300285. PubMed ID: 38427931
[TBL] [Abstract] [Full Text] [Related]
2. Sunitinib in Patients With breast cancer With
Calfa CJ; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Burness ML; Gogineni K; Rohatgi N; Al Baghdadi T; Conlin A; Gaba A; Hamid O; Krishnamurthy J; Gavini NJ; Gold PJ; Rodon J; Rueter J; Thota R; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2024 Feb; 8():e2300513. PubMed ID: 38354330
[TBL] [Abstract] [Full Text] [Related]
3. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract] [Full Text] [Related]
4. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases.
Roskoski R
Pharmacol Res; 2024 Jan; 199():107036. PubMed ID: 38096958
[TBL] [Abstract] [Full Text] [Related]
5. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
6. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the treatment of FGFR-Aberrant Tumors.
Javle M; King G; Spencer K; Borad MJ
Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
[TBL] [Abstract] [Full Text] [Related]
7. Futibatinib: First Approval.
Syed YY
Drugs; 2022 Dec; 82(18):1737-1743. PubMed ID: 36441501
[TBL] [Abstract] [Full Text] [Related]
8. Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
Davis AA; Gerratana L; Clifton K; Medford AJ; Velimirovic M; Hensing WL; Bucheit L; Shah AN; D'Amico P; Reduzzi C; Zhang Q; Dai CS; Denault EN; Bagegni NA; Opyrchal M; Ademuyiwa FO; Bose R; Gradishar WJ; Behdad A; Ma CX; Bardia A; Cristofanilli M
EBioMedicine; 2022 Dec; 86():104316. PubMed ID: 36332363
[TBL] [Abstract] [Full Text] [Related]
9. Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population.
Lai X; Yu R; Ou Q; Bao H; Wu X; Shao Y; Li Y; Zhang Y; Ding Q
Cancer Med; 2023 Mar; 12(5):6009-6015. PubMed ID: 36325957
[TBL] [Abstract] [Full Text] [Related]
10. The prognostic and predictive values of differential expression of exosomal receptor tyrosine kinases and associated with the PI3K/AKT/mTOR signaling in breast cancer patients undergoing neoadjuvant chemotherapy.
Guney Eskiler G; Kazan N; Haciefendi A; Deveci Ozkan A; Ozdemir K; Ozen M; Kocer HB; Yilmaz F; Kaleli S; Sahin E; Bilir C
Clin Transl Oncol; 2023 Feb; 25(2):460-472. PubMed ID: 36181664
[TBL] [Abstract] [Full Text] [Related]
11. IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target.
Lin CY; Yu CJ; Shen CI; Liu CY; Chao TC; Huang CC; Tseng LM; Lai JI
Med Oncol; 2022 Sep; 39(12):242. PubMed ID: 36180600
[TBL] [Abstract] [Full Text] [Related]
12. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.
Patrad E; Khalighfard S; Amiriani T; Khori V; Alizadeh AM
Cell Oncol (Dordr); 2022 Dec; 45(6):1073-1117. PubMed ID: 36149600
[TBL] [Abstract] [Full Text] [Related]
13. Gastric carcinosarcoma with fgfr2 amplification under long-term control with pazopanib: a case report and literature review.
Hayashi H; Makiyama A; Okumura N; Yasufuku I; Saigo C; Takeuchi T; Miyazaki T; Tanaka Y; Matsuhashi N; Murase K; Takahashi T; Futamura M; Yoshida K
BMC Gastroenterol; 2022 Jul; 22(1):360. PubMed ID: 35902814
[TBL] [Abstract] [Full Text] [Related]
14. Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing.
Huang CC; Liu CY; Huang CJ; Hsu YC; Lien HH; Wong JU; Tai FC; Ku WH; Hung CF; Lin JT; Huang CS; Chiang HS
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163506
[TBL] [Abstract] [Full Text] [Related]
15. Genomic Understanding Reveals the Important Role of fgfr2 as Paeoniflorin Target for Circumventing breast cancer Resistance to Tamoxifen.
Wibowo MA; Nugroho EP; Hermawan A
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3949-3958. PubMed ID: 34967576
[TBL] [Abstract] [Full Text] [Related]
16. The Discovery of New Drug-Target Interactions for breast cancer treatment.
Song J; Xu Z; Cao L; Wang M; Hou Y; Li K
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946556
[TBL] [Abstract] [Full Text] [Related]
17. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring
Meric-Bernstam F; Bahleda R; Hierro C; Sanson M; Bridgewater J; Arkenau HT; Tran B; Kelley RK; Park JO; Javle M; He Y; Benhadji KA; Goyal L
Cancer Discov; 2022 Feb; 12(2):402-415. PubMed ID: 34551969
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract] [Full Text] [Related]
19. Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in cancer Signaling.
Ferguson HR; Smith MP; Francavilla C
Cells; 2021 May; 10(5):. PubMed ID: 34068954
[TBL] [Abstract] [Full Text] [Related]
20. Poor prognosis of male triple-positive breast cancer patients: a propensity score matched SEER analysis and molecular portraits.
Wang B; Wang H; Zhao A; Zhang M; Yang J
BMC Cancer; 2021 May; 21(1):523. PubMed ID: 33964913
[TBL] [Abstract] [Full Text] [Related]
[Next]
